ANTI-DIABETIC AGENTS Flashcards

1
Q

Transports and metabolizes glucose for
energy

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Stimulates storage of glucose in the liver
and muscles (glycogen)

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Signals the liver to stop the release of
glucose

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Enhances storage of dietary fat in adipose tissue

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Accelerates transports of amino acids
into cells

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mechanism of Action
- primarily acts in the liver, muscle and adipose by attaching to the receptors on cellular membranes facilitating the
passage of glucose, potassium and
magnesium

A

INSULIN (ANTI-DIABETIC DRUGS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

DERIVED FROM: Animal / human - pork ( one different amino acid) - beef ( four different amino acids)

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ROUTE: subQ, IV, IM

A

INSULIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SIDE EFFECTS & ADVERSE EFFECTS
SOMOGYI EFFECT - hypoglycemic conditions (2-4AM) ► Leads to Stimulate the release of hormones (cortisol, glucagons, and epinephrine) to increase blood glucose lipolysis, gluconeogenesis, glycogenolysis

A

HYPOGLYCEMIC OR INSULIN SHOCK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dawn phenomenon – requires increase
insulin dose in early morning hours due to
increased plasma glucose concentration
because of increased cortisol and growth
hormone secretion

A

HYPOGLYCEMIC OR INSULIN SHOCK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Manifestations of Dawn Phenomenon: H/A,
lightheadedness, nervousness, tremors, excess perspiration, cold clammy skin, tachycardia, slurred speech, memory lapses, confusion, seizure, blood glucose <60 mg/d

A

HYPOGLYCEMIC OR INSULIN SHOCK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  • Inadequate amount of insulin
  • Sugar cannot be metabolized, uses fatty
    acids for energy
A

KETOACIDOSIS (HYPERGLYCEMIC REACTION)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Manifestations: extreme thirst, fruity
breath,kussmaul breathing, rapid pulse, dry
mucous membrane, poor skin turgor, blood
glucose > 250 mg/dL

A

KETOACIDOSIS (HYPERGLYCEMIC REACTION)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Storing Insulin:
► Avoid exposure to extreme
temperature(should not be frozen or kept
indirect sunlight or a hot car)
► Before injection should be at room
temperature (less irritating to tissue)
► Unopened vials are refrigerated until
needed
► Once insulin has been opened: - At room
temperature for one month- In the refrigerator
for 3 months( lose their strength if otherwise)
► Pre- filled syringes should be stored in a
refrigerator and should be used within 1-2
weeks

A

AMBOT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

insulin is delivered from the device through plastic tube with a metal or plastic needle placed sub-q

A

INSULIN PUMP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  • Needle less
  • delivered directly through the skin in the fatty tissue
  • delivered under high pressure(stinging,pain,
    burning and bruising may occur)
A

INSULIN JET INJECTORS

17
Q

T OR F: Insulin injected in the abdomen may be absorbed more rapidly than the other sites

18
Q

Main area of injection:
abdomen, arms (posterior surface). thigh
(anterior surface) and hips

A

INSULIN INJECTION SITES

19
Q

depression under the skin surface; animal insulin

A

LIPOATROPHY

20
Q

a raised lump of knot on the skin surface

A

LIPOHYPERTROPHY

21
Q

T OR F: Systemic rotation within one anatomical
area is recommended to prevent lipodystrophy

22
Q

T OR F: Do not use the same site more than
once in a 2 – 3 week period

23
Q

T OR F: Injections should be 1.5 inches apart within the anatomical area

24
Q

T OR F: Heat, massage and exercise of the
injected area can increase absorption
rates = hypoglycaemia Injection into the
scar tissue may delay absorption

25
AKA: Oral hypoglycemic drugs Indication: DM type 2
ORAL ANTIDIABETIC DRUGS
26
stimulate pancreatic beta cells to secrete more insulin; increase the insulin receptors; increasing the ability of the cells to bind insulin for glucose metabolism
SULFONYLUREAS
27
short- acting: tolbutamide(Orinase)
FIRST GENERATION SULFONYLUREAS
28
intermediate acting: acetohexamide( Dymelor), tolazamide (Tolinase)
FIRST GENERATION SULFONYLUREAS
29
long- acting: chlorpropamide(Diabinese)
FIRST GENERATION SULFONYLUREAS
30
glimepiride (Amaryl); glipizide(Glucotrol)
2ND GENERATION SULFONYLUREAS
31
decrease hepatic production of glucose from stored glycogen
BIGUANIDES (NON SULFONYLUREAS)
32
- Glucosidase Inhibitor –inhibit digestive enzyme in the small intestine responsible for the release of glucose from complex CHina diet
ALPHA (NON SULFONYLUREAS)
33
stimulate beta cells to release insulin
MEGLITINIDES (NON SULFONYLUREAS)
34
increase level of incretin hormones, increase insulin secretion, decreased glucagon secretion.
MODIFIER
35
Metformin
BIGUANIDES (NON SULFONYLUREAS)
36
acarbose; miglitol
ALPHA (NON SULFONYLUREAS)
37
repaglinide ; nateglinide D. Incretin
MEGLITINIDES (NON SULFONYLUREAS)